Spots Global Cancer Trial Database for donor lymphocyte infusion
Every month we try and update this database with for donor lymphocyte infusion cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Naive T-Cell Depleted DLI Following Allo Stem Cell Transplant | NCT01627275 | Hematological M... | Naive T Cell De... | 18 Years - | Duke University | |
| MRD-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allo-HSCT | NCT02673008 | Minimal Residua... Donor Lymphocyt... Hematopoietic S... Relapse | donor lymphocyt... | 14 Years - 65 Years | Nanfang Hospital, Southern Medical University | |
| Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation | NCT00795548 | Myelodysplastic... Acute Myeloid L... | 5-Azacitidine | 18 Years - | Heinrich-Heine University, Duesseldorf | |
| Haploidentical Stem Cell Transplantation for Children With Therapy Resistant Leukemia | NCT01025778 | Acute Lymphobla... Acute Myeloid L... | Clofarabine for... Etoposide for r... Cyclophosphamid... Clofarabine in ... Thiotepa in con... Melfalan in con... Haploidentical ... Donor lymphocyt... | 1 Year - 21 Years | Lund University Hospital | |
| A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity | NCT03032783 | Hematopoietic a... | Total-Body Irra... Donor Lymphocyt... Cyclophosphamid... Tacrolimus Mycophenolate M... Allogeneic Hema... | 18 Years - | Thomas Jefferson University | |
| Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation. | NCT02017457 | Acute Myelogeno... Myelodysplastic... | Donor lymphocyt... Azacytidine | 18 Years - | University Hospital of Mont-Godinne | |
| Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) | NCT04582864 | Relapsed Acute ... | Flotetuzumab Donor lymphocyt... | 18 Years - | Washington University School of Medicine | |
| Naive T-Cell Depleted DLI Following Allo Stem Cell Transplant | NCT01627275 | Hematological M... | Naive T Cell De... | 18 Years - | Duke University | |
| Prophylactic Donor Lymphocyte Infusion After Allo-PBSCT for Patients With Very High-risk Hematologic Malignancies | NCT03771222 | Donor Lymphocyt... Peripheral Bloo... Relapse Graft-versus-ho... Decitabine | Prophylactic DL... | 14 Years - 65 Years | Chinese PLA General Hospital | |
| Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant | NCT05031897 | Acute Lymphobla... Acute Myeloid L... Aplastic Anemia Chronic Lymphoc... Chronic Myelomo... Essential Throm... Hematopoietic a... Hodgkin Lymphom... Myelodysplastic... Myelofibrosis Myeloid Leukemi... Myeloid Neoplas... Non-Hodgkin Lym... Plasma Cell Mye... Polycythemia Ve... Small Lymphocyt... | Hematopoietic C... Mycophenolate M... Tacrolimus Cyclophosphamid... Total-Body Irra... Donor Lymphocyt... Fludarabine Melphalan | 18 Years - | Thomas Jefferson University | |
| 2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies | NCT03712878 | Hematopoietic a... | Total-Body Irra... Donor Lymphocyt... Cyclophosphamid... Allogeneic Hema... Tacrolimus Mycophenolate M... | 18 Years - | Thomas Jefferson University | |
| Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant | NCT03537599 | Minimal Residua... Recurrent Acute... Recurrent Adult... Recurrent Child... | Daratumumab Donor Lymphocyt... Laboratory Biom... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation | NCT06297629 | Allogeneic Stem... | ASTX727 Donor Lymphocyt... | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Naive T-Cell Depleted DLI Following Allo Stem Cell Transplant | NCT01627275 | Hematological M... | Naive T Cell De... | 18 Years - | Duke University | |
| Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion | NCT00966810 | Philadelphia Ch... | Stem cell trans... | 18 Years - 65 Years | Rambam Health Care Campus | |
| Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia | NCT00167167 | Leukemia, Myelo... AML MDS Leukemia, Lymph... | Donor Lymphocyt... | 1 Year - 60 Years | Masonic Cancer Center, University of Minnesota | |
| MRD-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allo-HSCT | NCT02673008 | Minimal Residua... Donor Lymphocyt... Hematopoietic S... Relapse | donor lymphocyt... | 14 Years - 65 Years | Nanfang Hospital, Southern Medical University | |
| Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation | NCT00984165 | Hodgkin's Lymph... Non-Hodgkin's L... Chronic Lymphoc... Multiple Myelom... | Single fraction... Donor Lymphocyt... Apheresis | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Prophylactic Donor Lymphocyte Infusion After Allo-PBSCT for Patients With Very High-risk Hematologic Malignancies | NCT03771222 | Donor Lymphocyt... Peripheral Bloo... Relapse Graft-versus-ho... Decitabine | Prophylactic DL... | 14 Years - 65 Years | Chinese PLA General Hospital | |
| Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene | NCT01875237 | Leukemia Myeloma Myeloproliferat... | Fludarabine Melphalan Alemtuzumab Stem Cell infus... Tacrolimus Mini Methotrexa... G-CSF Donor Lymphocyt... AP1903 Methylprednisol... Questionnaire | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant | NCT03537599 | Minimal Residua... Recurrent Acute... Recurrent Adult... Recurrent Child... | Daratumumab Donor Lymphocyt... Laboratory Biom... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation | NCT02458235 | Acute Myelogeno... Acute Lymphoid ... Juvenile Myelom... Myelodysplastic... | azacitidine donor lymphocyt... | - 29 Years | University of California, San Francisco | |
| Haploidentical Stem Cell Transplantation in Neuroblastoma | NCT00790413 | Neuroblastoma | iodine I 131 me... Fludarabine Thiotepa T-cell depletio... Haploidentical ... Donor Lymphocyt... Rituximab Co-transplantat... | 6 Months - 21 Years | Lund University Hospital | |
| Prophylactic Donor Lymphocyte Infusion After Allo-PBSCT for Patients With Very High-risk Hematologic Malignancies | NCT03771222 | Donor Lymphocyt... Peripheral Bloo... Relapse Graft-versus-ho... Decitabine | Prophylactic DL... | 14 Years - 65 Years | Chinese PLA General Hospital | |
| Post Transplant Donor Lymphocyte Infusion | NCT00167180 | Leukemia, Myelo... Lymphomas Multiple Myelom... Myelodysplastic... Leukemia, Lymph... Leukemia, Lymph... AML | Donor Lymphocyt... Induction Chemo... | 1 Year - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab | NCT03982992 | B Cell Precurso... B-Cell Acute Ly... Acute Lymphobla... Acute Lymphobla... Acute Lymphobla... | Blinatumomab in... | 18 Years - | Ludwig-Maximilians - University of Munich | |
| Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion | NCT00966810 | Philadelphia Ch... | Stem cell trans... | 18 Years - 65 Years | Rambam Health Care Campus | |
| A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation | NCT06297629 | Allogeneic Stem... | ASTX727 Donor Lymphocyt... | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Suicide Gene Therapy for Donor Lymphocytes Infusion After Allogeneic Hematopoietic Stem Cell Transplantation | NCT01086735 | Hematological M... | donor lymphocyt... | 18 Years - 70 Years | Assistance Publique - Hôpitaux de Paris | |
| IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation | NCT04628338 | Myelodysplastic... Myeloid Leukemi... Allogeneic Stem... | IFN-γ (interfer... | 18 Years - | University of Pittsburgh | |
| Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant | NCT03297528 | Donor Lymphocyt... Allogeneic Hema... Acute Leukemia Minimal Residua... Graft-versus-ho... Relapse | donor lymphocyt... | 5 Years - 60 Years | Peking University People's Hospital | |
| IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation | NCT04628338 | Myelodysplastic... Myeloid Leukemi... Allogeneic Stem... | IFN-γ (interfer... | 18 Years - | University of Pittsburgh | |
| Suicide Gene Therapy for Donor Lymphocytes Infusion After Allogeneic Hematopoietic Stem Cell Transplantation | NCT01086735 | Hematological M... | donor lymphocyt... | 18 Years - 70 Years | Assistance Publique - Hôpitaux de Paris | |
| Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) | NCT06158100 | Acute Myeloid L... | Venetoclax Azacitidine Donor Lymphocyt... | 18 Years - 75 Years | University of Miami | |
| Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant | NCT03297528 | Donor Lymphocyt... Allogeneic Hema... Acute Leukemia Minimal Residua... Graft-versus-ho... Relapse | donor lymphocyt... | 5 Years - 60 Years | Peking University People's Hospital | |
| Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation | NCT00795548 | Myelodysplastic... Acute Myeloid L... | 5-Azacitidine | 18 Years - | Heinrich-Heine University, Duesseldorf | |
| Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) | NCT04582864 | Relapsed Acute ... | Flotetuzumab Donor lymphocyt... | 18 Years - | Washington University School of Medicine | |
| IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation | NCT04628338 | Myelodysplastic... Myeloid Leukemi... Allogeneic Stem... | IFN-γ (interfer... | 18 Years - | University of Pittsburgh | |
| Post Transplant Donor Lymphocyte Infusion | NCT00167180 | Leukemia, Myelo... Lymphomas Multiple Myelom... Myelodysplastic... Leukemia, Lymph... Leukemia, Lymph... AML | Donor Lymphocyt... Induction Chemo... | 1 Year - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia | NCT00167167 | Leukemia, Myelo... AML MDS Leukemia, Lymph... | Donor Lymphocyt... | 1 Year - 60 Years | Masonic Cancer Center, University of Minnesota | |
| Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant | NCT05031897 | Acute Lymphobla... Acute Myeloid L... Aplastic Anemia Chronic Lymphoc... Chronic Myelomo... Essential Throm... Hematopoietic a... Hodgkin Lymphom... Myelodysplastic... Myelofibrosis Myeloid Leukemi... Myeloid Neoplas... Non-Hodgkin Lym... Plasma Cell Mye... Polycythemia Ve... Small Lymphocyt... | Hematopoietic C... Mycophenolate M... Tacrolimus Cyclophosphamid... Total-Body Irra... Donor Lymphocyt... Fludarabine Melphalan | 18 Years - | Thomas Jefferson University | |
| Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant | NCT02477878 | Leukemia Myelodysplastic... Lymphoma Multiple Myelom... Hematologic Neo... | BPX-501 Rimiducid | 18 Years - 65 Years | Bellicum Pharmaceuticals | |
| Haploidentical Stem Cell Transplantation in Neuroblastoma | NCT00790413 | Neuroblastoma | iodine I 131 me... Fludarabine Thiotepa T-cell depletio... Haploidentical ... Donor Lymphocyt... Rituximab Co-transplantat... | 6 Months - 21 Years | Lund University Hospital | |
| Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab | NCT03982992 | B Cell Precurso... B-Cell Acute Ly... Acute Lymphobla... Acute Lymphobla... Acute Lymphobla... | Blinatumomab in... | 18 Years - | Ludwig-Maximilians - University of Munich | |
| Infusion of Donor Lymphocytes Depleted of CD25+ Regulatory T-cells in Patients With Relapsed Hematologic Malignancies | NCT00675831 | Hematologic Mal... | CliniMACS CD25 ... | 18 Years - | Dana-Farber Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
